Rimonabant, white powder, pharmaceutiful chemical, pharmaceutiful ram material, anabolic steroid ,
Detailed Product Description
Rimonabant (also known as SR141716; trade name Acomplia) is an anorectic antiobesity drug that has been withdrawn from the market due to potentially serious side effects. It was approved for use in Europe and other countries, but never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1.It has also been shown to be a μ-opioid receptor antagonist (possibly the contributing factor in its reported dysphoric qualities). Its main effect is reduction in appetite.